LOUISVILLE, CO--(Marketwire - May 20, 2008) - GlobeImmune, Inc. announced today completion of the planned enrollment of 120 subjects in a Phase 2 clinical trial to evaluate the GI-5005 Tarmogen® for the treatment of patients with chronic hepatitis C infection. GI-5005 is being evaluated as a potential therapy in combination with standard of care; pegylated interferon plus ribavirin.
